JACC - "Bivalirudin Versus Heparin Anticoagulation in Transcatheter Aortic Valve Replacement"

"Bivalirudin Versus Heparin Anticoagulation in Transcatheter Aortic Valve Replacement"

"Conclusions  In this randomized trial of TAVR procedural pharmacotherapy, bivalirudin did not reduce rates of major bleeding at 48 h or net adverse cardiovascular events within 30 days compared with heparin. Although superiority was not shown, the noninferiority hypothesis was met with respect to the latter factor. Given the lower cost, heparin should remain the standard of care, and bivalirudin can be an alternative anticoagulant option in patients unable to receive heparin in TAVR"

http://content.onlinejacc.org/article.aspx?articleID=2461781